Cargando…

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA

The RASSF1A promoter is frequently methylated in high-grade serous ovarian cancer (HGSC). We examined RASSF1A promoter methylation in primary tumors, adjacent morphologically tumor cell-free tissues and corresponding circulating tumor DNA (ctDNA) samples of patients with HGSC, using a real-time meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannopoulou, Lydia, Chebouti, Issam, Pavlakis, Kitty, Kasimir-Bauer, Sabine, Lianidou, Evi S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400595/ https://www.ncbi.nlm.nih.gov/pubmed/28206954 http://dx.doi.org/10.18632/oncotarget.15249

Ejemplares similares

Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
por: Stergiopoulou, Dimitra, et al.
Publicado: (2022)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer
por: Strati, Areti, et al.
Publicado: (2013)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Image-Based Identification and Genomic Analysis of Single Circulating Tumor Cells in High Grade Serous Ovarian Cancer Patients
por: Salmon, Carolin, et al.
Publicado: (2021)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

Advances in circulating tumor cells (ACTC): from basic research to clinical practice
por: Lianidou, Evi S, et al.
Publicado: (2013)

RASSF6; the Putative Tumor Suppressor of the RASSF Family
por: Iwasa, Hiroaki, et al.
Publicado: (2015)

What's new on circulating tumor cells? A meeting report
por: Lianidou, Evi S, et al.
Publicado: (2010)

Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer
por: Zavridou, Martha, et al.
Publicado: (2021)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2022)

Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients
por: Mach, Pawel, et al.
Publicado: (2021)

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
por: van Zogchel, Lieke M. J., et al.
Publicado: (2020)

The Role of RASSF1C in the Tumor Microenvironment
por: Amaar, Yousef G., et al.
Publicado: (2023)

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR
por: Strati, Areti, et al.
Publicado: (2011)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous Carcinoma
por: Ruano, Anna Paula Carreta, et al.
Publicado: (2022)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
por: Strati, Areti, et al.
Publicado: (2019)

FGF/FGFR1 system in paired breast tumor-adjacent and tumor tissues, associations with mammographic breast density and tumor characteristics
por: Boraka, Öykü, et al.
Publicado: (2023)

Regulation of RASSF by non-coding RNAs in different cancers: RASSFs as masterminds of their own destiny as tumor suppressors and oncogenes
por: Farooqi, Ammad Ahmad, et al.
Publicado: (2022)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
por: Markou, Athina, et al.
Publicado: (2020)

Epigenetically inactivated RASSF1A as a tumor biomarker
por: Raos, Dora, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors
por: van Zogchel, Lieke M. J., et al.
Publicado: (2021)

Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors
por: Malpeli, Giorgio, et al.
Publicado: (2011)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_unigo6smuppprdooaui6i8tjk4